The treatment landscape for multiple myeloma continues to evolve rapidly, offering renewed hope to patients and clinicians alike. In a major regulatory milestone, the U.S. Food and Drug Administration has approved a new quadruplet therapy for adults with newly diagnosed multiple myeloma who are not eligible for autologous stem cell transplant. This decision expands frontline treatment options and reinforces the growing role of antibody-based regimens in early myeloma care.
The newly approved combination includes Darzalex Faspro, also known as daratumumab and hyaluronidase fihj, alongside bortezomib, lenalidomide, and dexamethasone. The regimen is commonly referred to as D-VRd. According to experts, this approval represents a significant step toward improving depth of response and long term disease control for a population that has historically faced limited therapeutic options.
Multiple myeloma is a cancer of plasma cells that accumulate in the bone marrow and interfere with the production of healthy blood cells. It is considered a chronic and relapsing disease, although outcomes have improved dramatically over the past two decades due to novel therapies.
Autologous stem cell transplant has long been a standard part of frontline therapy for eligible patients. However, many adults with newly diagnosed multiple myeloma are not candidates for transplant due to age, comorbidities, or overall health status. For these patients, effective non-transplant regimens are critical.
The FDA approval of D-VRd specifically addresses this unmet need by offering a highly effective option for transplant-ineligible patients at the time of diagnosis.
Darzalex Faspro is a subcutaneous formulation of daratumumab, a monoclonal antibody that targets CD38. CD38 is a protein highly expressed on multiple myeloma cells. By binding to CD38, daratumumab helps the immune system identify and destroy cancerous plasma cells through multiple mechanisms, including immune-mediated cell death.
Darzalex Faspro differs from intravenous daratumumab in that it is administered as a subcutaneous injection, which reduces administration time and improves patient convenience. This formulation has already been approved for several indications in multiple myeloma, both in newly diagnosed and relapsed or refractory settings.
With this latest approval, Darzalex Faspro now holds twelve FDA approved indications overall, five of which are in newly diagnosed multiple myeloma. This reinforces its status as a foundational therapy in modern myeloma treatment.
The FDA approved Darzalex Faspro in combination with bortezomib, lenalidomide, and dexamethasone for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant.
Notably, D-VRd is now the only anti CD38 antibody based regimen with approved indications across newly diagnosed patients regardless of transplant eligibility. This distinction highlights its broad applicability and clinical significance.
Approval of Darzalex Faspro was granted to Johnson and Johnson, the pharmaceutical company responsible for its development and commercialization.
The FDA decision was supported by data from the phase 3 CEPHEUS trial, a large randomized study that enrolled 395 patients with newly diagnosed multiple myeloma who were ineligible for transplant.
The trial compared the D-VRd regimen against the standard triplet therapy of bortezomib, lenalidomide, and dexamethasone, often referred to as VRd.
At a median follow-up of 22 months, results demonstrated a clear advantage for the quadruplet regimen. The overall minimal residual disease negativity rate at a sensitivity of 10 to the minus 5 was 52.3 percent in the D-VRd group compared with 34.8 percent in the VRd group. Minimal residual disease negativity means no detectable cancer cells among 100,000 bone marrow cells and is considered a strong predictor of long-term outcomes.
The benefits of D-VRd became even more pronounced over time. At a median follow up of 39 months, the proportion of patients achieving sustained minimal residual disease negativity for at least twelve months nearly doubled in the D-VRd arm, reaching 42.6 percent compared with 25.3 percent in the VRd group.
In terms of disease control, D-VRd significantly reduced the risk of progression or death, with a hazard ratio of 0.60 compared with VRd alone. This indicates a 40 percent reduction in risk, a meaningful improvement for patients facing a serious and life-limiting condition.
Depth of response also favored the quadruplet therapy. At a median follow-up of 59 months, 81.2 percent of patients treated with D-VRd achieved a complete response or better, compared with 61.6 percent in the VRd group.
Minimal residual disease has become an increasingly important endpoint in multiple myeloma research. Achieving MRD negativity is associated with longer progression-free survival and overall survival across multiple studies.
The ability of D-VRd to produce higher rates of both MRD negativity and sustained MRD negativity suggests that this regimen not only works quickly but also provides durable disease control. For transplant-ineligible patients, who often rely on long-term therapy rather than intensive consolidation strategies, this durability is especially important.
Industry leaders and clinical experts have emphasized the importance of this FDA decision. June Lanoue from Johnson and Johnson Innovative Medicine described the approval as a milestone that underscores the role of Darzalex Faspro as a foundational therapy for both newly diagnosed and relapsed or refractory multiple myeloma.
She noted that the CEPHEUS trial demonstrated the efficacy of a Darzalex Faspro-based quadruplet as a frontline standard of care. According to Lanoue, allowing patients to receive D-VRd at the time of diagnosis represents an important step toward the long-term goal of achieving a functional cure for multiple myeloma.
For patients newly diagnosed with multiple myeloma who are not candidates for transplant, the approval of D-VRd offers a powerful new option. The regimen combines four agents with complementary mechanisms of action, resulting in deeper responses without requiring transplant.
Clinicians now have greater flexibility to tailor frontline therapy based on patient characteristics, preferences, and treatment goals. The availability of a subcutaneous anti CD38 antibody also improves treatment logistics and patient experience.
From a broader perspective, this approval reflects a continuing shift toward earlier use of highly effective combination therapies in multiple myeloma. Rather than reserving the most potent agents for later lines of therapy, current strategies aim to achieve the deepest possible response upfront.
The approval of D-VRd adds momentum to ongoing research efforts focused on improving outcomes in multiple myeloma. Clinical trials continue to explore novel combinations, maintenance strategies, and immune-based therapies, including bispecific antibodies and cellular therapies.
As more patients achieve deep and sustained responses early in the course of disease, the concept of multiple myeloma as a manageable chronic condition becomes increasingly realistic. Regulatory decisions like this one play a key role in translating clinical trial success into real-world patient benefit.
The FDA approval of Darzalex Faspro in combination with bortezomib, lenalidomide, and dexamethasone marks a major advance for adults with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant. Backed by robust phase 3 trial data, the D-VRd regimen delivers higher rates of minimal residual disease negativity, deeper responses, and reduced risk of progression or death compared with standard therapy.
As the only anti CD38 antibody based regimen approved across newly diagnosed patients regardless of transplant eligibility, D-VRd sets a new benchmark for frontline treatment. For patients and providers navigating the complexities of multiple myeloma care, this approval represents both progress and promise.
“DARZALEX FASPRO®-based quadruplet regimen approved in the U.S. for newly diagnosed patients with multiple myeloma who are transplant ineligible,” JNJ.com, Jan. 27, 2026. https://www.jnj.com/media-center/press-releases/darzalex-faspro-based-quadruplet-regimen-approved-in-the-u-s-for-newly-diagnosed-patients-with-multiple-myeloma-who-are-transplant-ineligible
This article is for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment. Clinical trial data reflect general outcomes and may not apply to individual patients. Treatment decisions should always be made in consultation with a qualified healthcare professional who can consider individual medical history, condition, and treatment goals.
Most Accurate Healthcare AI designed for everything from admin workflows to clinical decision support.